Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks MBr J Haematol 2009[Mar]; 144 (5): 677-85Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy. Identifying patients most at risk of developing FN might help physicians to target prophylactic treatment with colony-stimulating factor (CSF), in order to decrease the incidence, or duration, of myelosuppression and facilitate delivery of chemotherapy as planned. We present a risk model for FN occurrence in the first cycle of chemotherapy, based on a subgroup of 240 patients with non-Hodgkin lymphoma (NHL) enroled in our European prospective observational study. Eligible patients had an International Prognostic Index of 0-3, and were scheduled to receive a new myelosuppressive chemotherapy regimen with at least four cycles. Clinically relevant factors significantly associated with cycle 1 FN were older age, increasing planned cyclophosphamide dose, a history of previous chemotherapy, a history of recent infection, and low baseline albumin (<35 g/l). Prophylactic CSF use and higher weight were associated with a significant protective effect. The model had high sensitivity (81%) and specificity (80%). Our model, together with treatment guidelines, may rationalise the clinical decision of whether to support patients with CSF primary prophylaxis based on their risk factor profile. Further validation is required.|Adolescent[MESH]|Adult[MESH]|Age Factors[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/administration & dosage/adverse effects[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects[MESH]|Area Under Curve[MESH]|Body Weight[MESH]|Colony-Stimulating Factors/therapeutic use[MESH]|Cyclophosphamide/administration & dosage/adverse effects/therapeutic use[MESH]|Doxorubicin/administration & dosage/adverse effects[MESH]|Europe[MESH]|Female[MESH]|Humans[MESH]|Immunosuppressive Agents/adverse effects/therapeutic use[MESH]|Logistic Models[MESH]|Lymphoma, Non-Hodgkin/drug therapy/*immunology[MESH]|Male[MESH]|Middle Aged[MESH]|Neutropenia/*chemically induced/drug therapy[MESH]|Prednisone/administration & dosage/adverse effects[MESH]|Prevalence[MESH]|Prognosis[MESH]|Prospective Studies[MESH]|Recombinant Proteins[MESH]|Risk Assessment/methods[MESH]|Rituximab[MESH]|Vincristine/administration & dosage/adverse effects[MESH]|Young Adult[MESH] |